LIXTE Biotechnology regains Nasdaq equity compliance after $6.5M capital raise

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Received Nasdaq hearings panel notice of compliance with Listing Rule 5550(b)(1) requiring min $2.5M equity.
Compliance achieved after closing $5.0M placement (July 2) and $1.5M direct offering (July 8).
Subject to Panel Monitor through July 15, 2026; further deficiency triggers immediate hearing requirement.
CEO states regaining compliance underscores financial health as clinical trials progress in ovarian, colon, sarcoma.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.